Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.9Last Year’s EPS
0.68Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top- and bottom-line growth, record Q4 results, margin expansion, rapid synergy realization (NuVasive synergies ahead of plan), and earlier-than-expected accretion from Nevro. Management raised EPS guidance and reaffirmed revenue guidance for 2026 while outlining plans for continued R&D investment and capital placement flexibility. Offsetting these positives were early-year operational and Enabling Tech lumpiness, international supply chain and regional challenges, integration risk for Nevro, a meaningful decline in the cash balance due to acquisitions, debt paydown and buybacks, and temporary one-time charges. Overall, the highlights (robust revenue and profit growth, margin improvement, successful synergy capture, and raised guidance) outweigh the lowlights, which are largely short- to medium-term execution and integration issues.Company Guidance
Record Quarterly and Annual Financial Performance
Q4 2025 revenue of $826.4M (+25.7% YoY, +24.7% constant currency) and full year 2025 revenue of $2.939B (+16.7% as-reported, +16.2% constant currency); Q4 non-GAAP EPS $1.28 (+52.1% YoY) and full year non-GAAP EPS $3.98 (+30.8% YoY).
Strong Base Business Growth
Q4 base business revenue $726.7M (+10.6% YoY) and consolidated base business organic growth in H2 2025 of 8.8%; U.S. Spine grew ~10% in Q4 with 48 consecutive weeks of growth, indicating durable above-market momentum.
Enabling Technologies Momentum
Q4 Enabling Technologies sales $55.6M (+18.5% YoY), achieved record sales in dollars and units for the capital portfolio and ExcelsiusGPS robotic system; pipeline deals closed in Q4 after earlier elongation.
Trauma and Product Launch Success
Trauma business grew ~27% in Q4 (26.8% reported) driven by legacy trauma uptake and demand for new launches such as the ANTHEM elbow plating system which has exceeded expectations.
Margin Expansion and Profitability
Adjusted gross profit margin expanded to 69.2% in Q4 2025 (vs. 67.1% prior year); legacy Globus adjusted EBITDA margin reached 35.7% in Q4 and consolidated adjusted EBITDA margin was 33.9%; full year adjusted EBITDA 31.3%.
Synergy Execution Outperforming Plan
Actioned $200M of NuVasive synergies (target $170M) ahead of schedule by ~$30M and achieved sequential improvements across the P&L; free cash flow generation increased ~150% from $81.8M (Q4 2023) to $202.4M (Q4 2025).
Nevro Integration and Accretion
Nevro added $293.6M revenue for the full year and $99.7M in Q4 with a stand-alone adjusted EBITDA margin of 21.2% in Q4; Nevro became EPS accretive within the first 9 months post-acquisition, 15 months ahead of initial guidance.
Improving GAAP Metrics and Debt Reduction
GAAP gross margin improved to 65.7% in Q4 (vs. 57.2% prior year), driven by lower inventory step-up amortization; fully repaid $450M convertible debt assumed in merger, reducing interest expense.
Capital Allocation and Shareholder Returns
During 2025 repurchased ~4.3M shares for $300.5M and repurchased $45M in Q4; $390M of share repurchase authorization remains under a $500M program while prioritizing internal investment and CapEx (guidance 5-6% of sales).
2026 Financial Guidance Upheld and EPS Raised
Reaffirmed 2026 revenue guidance of $3.18B to $3.22B (implied growth 8.2%–9.6%) and increased full-year non-GAAP EPS guidance to $4.40–$4.50 (implied growth 10.6%–13.1%), reflecting confidence in continued margin expansion.
GMED Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GMED Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $91.88 | $96.22 | +4.72% |
Nov 06, 2025 | $61.71 | $83.89 | +35.94% |
Aug 07, 2025 | $54.07 | $58.65 | +8.47% |
May 08, 2025 | $72.46 | $55.82 | -22.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Globus Medical (GMED) report earnings?
Globus Medical (GMED) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is Globus Medical (GMED) earnings time?
Globus Medical (GMED) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMED EPS forecast?
GMED EPS forecast for the fiscal quarter 2026 (Q1) is 0.9.